Meet the Morphochem team
Morphochem is a clinical-stage pharmaceutical company located in Munich, Germany. We are a 100-percent subsidiary of Biovertis AG, which is headquartered in Vienna, Austria. Biovertis’s major shareholder is TVM Capital.
At Morphochem, we are committed to the development and commercialization of MCB3681, a compound that will provide the basis for an innovative intravenous therapy for severe Clostridium difficile infections. Our lean operations reflect our dedication to this purpose.